SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has been named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards (SRIA). The award recognizes the company's work in developing and commercializing robotic surgery technology, as announced in a press release.
The surgical robotics industry has become increasingly competitive as healthcare providers adopt robotic-assisted procedures across multiple specialties. The award was presented after SS Innovations was selected from a field of ten finalists that included Intuitive, Johnson & Johnson MedTech, Medtronic, Distalmotion, FUTEK, Meril, MicroPort, Precision IO Group, and THINK Surgical. According to the press release, the Surgical Robotics Industry Awards recognize one company each year in the Outstanding Company category based on criteria including commercial performance, technological innovation, societal impact, customer recognition, ethical standards, and workplace practices.
Chairman and Chief Executive Officer Dr. Sudhir Srivastava said the award reflects the company's focus on expanding access to robotic surgery while continuing to develop technologies intended to improve affordability for hospitals and healthcare systems.
The recognition coincides with continued operational growth for the company's flagship SSi Mantra surgical robotic platform. As of June 22, 2026, surgeons had completed a cumulative 11,719 multi-specialty procedures using the SSi Mantra system. Those procedures include 612 cardiac surgeries, 175 telesurgeries, and 212 pediatric operations. Physicians have now used the platform in more than 170 different types of surgical procedures.
Training has also expanded alongside system adoption. Approximately 2,100 physicians have completed training on the SSi Mantra platform, an important consideration for robotic surgery systems, where physician education and clinical familiarity often influence hospital purchasing decisions and long-term utilization.
The company's commercial footprint has continued to broaden internationally. To date, regulatory approvals have been granted in 14 countries: Colombia, Ecuador, Guatemala, Guyana, India, Indonesia, Iraq, Kenya, Nepal, Oman, the Philippines, Sri Lanka, Ukraine, and the United Arab Emirates. Those approvals provide opportunities for continued market expansion as healthcare systems evaluate robotic-assisted surgery across a wider range of procedures.
SS Innovations describes the SSi Mantra as a modular, multi-arm robotic surgery platform designed to support multiple surgical specialties. The system incorporates between three and five robotic arms, a three-dimensional 4K visualization system, an ergonomic surgeon console, and digital imaging capabilities. Its instrument portfolio includes more than 40 robotic surgical instruments, including smaller 5-millimeter instruments intended for pediatric and ear, nose, and throat procedures.
The company has also developed a portable tele-surgeon console, known as the SSi MantrAsana, which supports remote surgical capabilities. While telesurgery remains an emerging area, SS Innovations has reported performing more than 20 cardiac telesurgeries using the platform.
For more information, visit the company's website at www.SSInnovations.com. The latest news and updates relating to SSII are available in the company's newsroom at https://nnw.fm/SSII.
